PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-20
DOI
10.1038/s41598-019-53603-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Alcohol-related liver disease: Time for action
- (2019) Ramon Bataller et al. JOURNAL OF HEPATOLOGY
- Current trials and novel therapeutic targets for alcoholic hepatitis
- (2019) Ashwani K. Singal et al. JOURNAL OF HEPATOLOGY
- PCSK9 is Increased in Cerebrospinal Fluid of Individuals With Alcohol Use Disorder
- (2019) Ji Soo Lee et al. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
- Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice
- (2019) Paul F. Lebeau et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation
- (2018) Angelos D. Karagiannis et al. Current Atherosclerosis Reports
- The ever-expanding saga of the proprotein convertases and their roles in body homeostasis
- (2018) Nabil G. Seidah et al. CURRENT OPINION IN LIPIDOLOGY
- Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
- (2018) Theodosios D. Filippatos et al. CURRENT OPINION IN LIPIDOLOGY
- PCSK9 induces a pro-inflammatory response in macrophages
- (2018) Chiara Ricci et al. Scientific Reports
- Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population
- (2018) Matthieu Wargny et al. ATHEROSCLEROSIS
- Alcoholic liver disease
- (2018) Helmut K. Seitz et al. Nature Reviews Disease Primers
- Lipid-Lowering Drug Effects Beyond the Cardiovascular System: Relevance for Neuropsychiatric Disorders
- (2018) Falk W Lohoff INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis
- (2017) Partha Mukhopadhyay et al. JOURNAL OF HEPATOLOGY
- Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder
- (2017) F W Lohoff et al. MOLECULAR PSYCHIATRY
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury
- (2017) Yuping Wang et al. Scientific Reports
- Alcohol Vapor Inhalation as a Model of Alcohol-Induced Organ Disease
- (2016) Alan J. Mouton et al. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
- Liver fat accumulation is associated with circulating PCSK9
- (2016) Massimiliano Ruscica et al. ANNALS OF MEDICINE
- Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
- (2016) Vera Bittner CIRCULATION
- Linking Pathogenic Mechanisms of Alcoholic Liver Disease With Clinical Phenotypes
- (2016) Laura E. Nagy et al. GASTROENTEROLOGY
- Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
- (2016) Michel Farnier et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis
- (2016) Dhruva J. Dwivedi et al. SHOCK
- PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse LiverSignificance
- (2015) Annie Demers et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Cross-talk between LOX-1 and PCSK9 in vascular tissues
- (2015) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state
- (2015) Dick C. Chan et al. CLINICAL SCIENCE
- Role of PCSK9 beyond liver involvement
- (2015) Bertrand Cariou et al. CURRENT OPINION IN LIPIDOLOGY
- DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma
- (2015) Augusto Villanueva et al. HEPATOLOGY
- Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice
- (2015) Vikram Ravindra Shende et al. JOURNAL OF LIPID RESEARCH
- Alcoholic liver disease: mechanisms of injury and targeted treatment
- (2015) Alexandre Louvet et al. Nature Reviews Gastroenterology & Hepatology
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy
- (2015) Lee Joseph et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Genetics of Alcoholic Liver Disease
- (2015) Ann Daly et al. SEMINARS IN LIVER DISEASE
- Animals Models of Gastrointestinal and Liver Diseases. Animal models of alcohol-induced liver disease: pathophysiology, translational relevance, and challenges
- (2014) Stephanie Mathews et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease
- (2014) Sha Li et al. ATHEROSCLEROSIS
- Impact of fasting time on hepatic lipid metabolism in nutritional animal studies
- (2014) Ikuo Ikeda et al. BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
- Plasma proprotein convertase subtilisin–kexin type 9 is predominantly related to intermediate density lipoproteins
- (2014) Arjan J. Kwakernaak et al. CLINICAL BIOCHEMISTRY
- PCSK9 and LDLR degradation
- (2014) Thomas A. Lagace CURRENT OPINION IN LIPIDOLOGY
- Inhibition ofPCSK9Transcription by Berberine Involves Down-regulation of Hepatic HNF1α Protein Expression through the Ubiquitin-Proteasome Degradation Pathway
- (2014) Bin Dong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease
- (2014) Yan Zhang et al. Journal of Clinical Lipidology
- Liver transplantation for alcoholic liver disease
- (2014) Michael R. Lucey Nature Reviews Gastroenterology & Hepatology
- Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2014) Yoshihisa Takahashi WORLD JOURNAL OF GASTROENTEROLOGY
- Diagnosis of alcoholic liver disease
- (2014) Cara Torruellas WORLD JOURNAL OF GASTROENTEROLOGY
- Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis
- (2013) R. Parker et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ε2
- (2013) Martijn C. G. J. Brouwers et al. CLINICAL SCIENCE
- Liver sinusoidal endothelial cells and liver regeneration
- (2013) Laurie D. DeLeve JOURNAL OF CLINICAL INVESTIGATION
- Global burden of alcoholic liver diseases
- (2013) Jürgen Rehm et al. JOURNAL OF HEPATOLOGY
- Mouse model of chronic and binge ethanol feeding (the NIAAA model)
- (2013) Adeline Bertola et al. Nature Protocols
- Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
- (2013) Bertrand Cariou et al. Nutrition & Metabolism
- The PCSK9 decade
- (2012) Gilles Lambert et al. JOURNAL OF LIPID RESEARCH
- Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
- (2011) Bin Gao et al. GASTROENTEROLOGY
- Operant Behavior and Alcohol Levels in Blood and Brain of Alcohol-Dependent Rats
- (2009) Nicholas W. Gilpin et al. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
- Chronic Alcohol Consumption Disrupted Cholesterol Homeostasis in Rats: Down-Regulation of Low-Density Lipoprotein Receptor and Enhancement of Cholesterol Biosynthesis Pathway in the Liver
- (2009) Zhigang Wang et al. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
- PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia
- (2009) Bertrand Cariou et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Intravenous N-Acetylcysteine Improves Transplant-Free Survival in Early Stage Non-Acetaminophen Acute Liver Failure
- (2009) William M. Lee et al. GASTROENTEROLOGY
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Oxidative Stress and Alcoholic Liver Disease
- (2009) Defeng Wu et al. SEMINARS IN LIVER DISEASE
- Alcohol and lipid metabolism
- (2008) Margaret Sozio et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- Quantifying the risk for alcohol-use and alcohol-attributable health disorders: Present findings and future research needs
- (2008) Ting-Kai Li JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started